SBA-16 and two modified SBA-16 type ordered mesoporous silica were used as the carriers for ibuprofen (anti-inflammatory drug) and furosemide (loop diuretic drug). Modification of the solid carrier was prepared with chitosan or N-3[(amino(poly-propylenoxy)]aminopropyltrimethoxysilane. The samples of carriers and carrier-drug loaded materials were characterized by X-ray diffraction, N2 adsorption, Fourier-transform infrared spectroscopy, thermogravimetry, and differential scanning calorimetry. The release profiles of active pharmaceutical ingredients were performed in media with different pH in the USP 2 apparatus as well as in two biorelevant media (fasted state simulated gastric fluid and fasted state small intestinal fluid) in USP 4 apparatus. The loading of active substances into mesoporous materials was performed with modified immersion method. The maximum content of deposited drug in mesoporous material was close to 12.0 and 2.2 wt.% for ibuprofen and furosemide, respectively. After drug adsorption, the reduction of BET surface area, pore volume and pore diameter of non-modified and modified SBA-16 was observed, while the cubic arrays of siliceous matrix were well preserved. The release profiles of ibuprofen and furosemide loaded in mesoporous materials in media with different pH and biorelevant fasted state simulated gastric fluid and fasted state small intestinal fluid showed that the new SBA-16 type materials modify the release profiles of furosemide, increasing the dissolution rate of these substances in the medium at pH 1.2. The cytotoxicity of the materials and permeability of drugs after their loading on SBA-16 materials were evaluated on Caco-2 model. The results of our study showed that mesoporous materials did not exert cytotoxic effects and did not influence on the permeability of both active pharmaceutical ingredients in relation to pure substances.
Vallet-RegíMBalasFArcosD.Mesoporous materials for drug delivery. Angew Chem Int Ed Engl2007;
46: 7548–7558.
2.
Vallet-RegiMBalasFColillaMet al.
Drug confinement and delivery in ceramic implants. Drug Metab Lett2007;
1: 37–40.
3.
Vallet-RegíMRuiz-GonzálezLIzquierdo-BarbaIet al.
Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem2006;
16: 26–31.
4.
WangS.Ordered mesoporous materials for drug delivery. Micropor Mesopor Mater2009;
117: 1–9.
5.
HorcajadaPRámilaAFéreyGet al.
Influence of superficial organic modification of MCM-41 matrices on drug delivery rate. Solid State Sci2006;
8: 1243–1249.
6.
AiroldiCOliveiraVV.Hydrophobic contribution to amoxicillin release associated with organofunctionalized mesoporous SBA-16 carriers. Mater Res Bull2014;
59: 214–222.
ThomasMJKSlipperIWalunjAet al.
Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int J Pharm2010;
387: 272–277.
13.
HuYWangJZhiZet al.
Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J Colloid Interface Sci2011;
363: 410–417.
14.
HuYZhiZZhaoQet al.
3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol. Micropor Mesopor Mater2012;
147: 94–101.
15.
LopesSMNogueiraKABGamaMSet al.
Synthesis and characterization of ordered mesoporous silica (SBA-15 and SBA-16) for adsorption of biomolecules. Micropor Mesopor Mater2013;
180: 284–292.
16.
ZhuYFShiJLLiYSet al.
Storage and release of ibuprofen drug molecules in hollow mesoporous silica spheres with modified pore surface. Micropor Mesopor Mater2005;
85: 75–81.
17.
ManzanoMAinaVAreánCOet al.
Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. Chem Eng J2008;
137: 30–37.
18.
KamarudinNHNJalilAATriwahyonoSet al.
Variation of the crystal growth of mesoporous silica nanoparticles and the evaluation to ibuprofen loading and release. J Colloid Interface Sci2014;
421: 6–13.
HorcajadaPRámilaAPérez-ParienteJet al.
Influence of pore size of MCM-41 matrices on drug delivery rate. Micropor Mesopor Mater2004;
68: 105–109.
21.
KrukMJaroniecMSayariA.Application of large pore MCM-41 molecular sieves to improve pore size analysis using nitrogen adsorption measurements. Langmuir1997;
13: 6267–6273.
22.
QiFWuJFanQ-Zet al.
Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability. Colloid Surface B2013;
112: 492–498.
23.
European Pharmacopoeia Commission, Council of Europe. European pharmacopoeia. 8th ed.
Strasbourg:
European Directorate for the Quality of Medicines & Health Care, 2013.
24.
SalonenJLaitinenLKaukonenAMet al.
Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release2005;
108: 362–374.
25.
MesaMSierraLPatarinJet al.
Morphology and porosity characteristics control of SBA-16 mesoporous silica. Effect of the triblock surfactant pluronic F127 degradation during the synthesis. Solid State Sci2005;
7: 990–997.
26.
PetushkovAYoonSLarsenSC.Synthesis of hierarchical nanocrystalline ZSM-5 with controlled particle size and mesoporosity. Micropor Mesopor Mater2011;
137: 92–100.
27.
GrudzienRMGrabickaEBJaroniecM.Adsorption studies of thermal stability of SBA-16 mesoporous silicas. Appl Surf Sci2007;
253: 5660–5665.
28.
GoscianskaJOlejnikANowakIet al.
Ordered mesoporous silica modified with lanthanum for ibuprofen loading and release behaviour. Eur J Pharm Biopharm2015;
94: 550–558.
29.
LehtoVPVähä-HeikkiläKPaskiJet al.
Use of thermoanalytical methods in quantification of drug load in mesoporous silicon microparticles. J Therm Anal Calorim2005;
80: 393–397.
30.
SalonenJPaskiJVähä-HeikkiläKet al.
Determination of drug load in porous silicon microparticles by calorimetry. Phys Stat Sol (A)2005;
202: 1629–1633.
31.
HirvonenJLaaksonenTPeltonenLet al.
Feasibility of silicon-based mesoporous materials for oral drug delivery applications. Dosis2008;
24: 129–149.
32.
HeikkiläTSalonenJTuuraJet al.
Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv2007;
14: 337–347.
33.
ThommesMKanekoKNeimarkAVet al.
Physisorption of gases, with special reference to the evaluation of surface area and pore size distribution (IUPAC Technical Report). Pure Appl Chem2015;
87: 1051–1069.
34.
OtsukaKWagnerCSelenAet al.
Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro–in-silico–in-vivo approach. J Pharm Pharmacol2015;
67: 651–665.
35.
AmbrogiVPerioliLPaganoCet al.
Use of SBA-15 for furosemide oral delivery enhancement. Eur J Pharm Sci2012;
46: 43–48.
36.
LinCXQiaoSZYuCZet al.
Periodic mesoporous silica and organosilica with controlled morphologies as carriers for drug release. Micropor Mesopor Mater2009;
117: 213–219.
37.
Izquierdo-BarbaIMartinezADoadrioALet al.
Release evaluation of drugs from ordered three-dimensional silica structures. Eur J Pharm Sci2005;
26: 365–373.
Díaz-MoralesUBellussiGCaratiAet al.
Ethane-silica hybrid material with ordered hexagonal mesoporous structure. Micropor Mesopor Mater2006;
87: 185–191.
40.
XiaYMokayaR.High surface area ethylene-bridged mesoporous and supermicroporous organosilica spheres. Micropor Mesopor Mater2005;
86: 231–242.
41.
QuFZhuGLinHet al.
A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials. J Solid State Chem2006;
179: 2027–2035.
42.
FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate-R, 2015.
43.
HeikkiläTSalonenJTuuraJet al.
Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm2007;
331: 133–138.
44.
ZhangYHuoMZhouJet al.
DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J2010;
12: 263–271.
45.
USP 38 – NF 33. The United States Pharmacopeia and National Formulary 2015 main edition plus supplements 1 and 2.
Stuttgart:
Deutscher Apotheker Verlag, 2015.
46.
TsumeYMudieDMLangguthPet al.
The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci2014;
57: 152–163.
RefsgaardHFHJensenBFBrockhoffPBet al.
In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem2005;
48: 805–811.
49.
PhamTheHGonzalez-IvarezIBermejoMet al.
In silico prediction of Caco-2 cell permeability by a classification QSAR approach. Mol Inform2011;
30: 376–385.
